Rabab Abdel Moneim | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Dr. Rabab Abdel Moneim | Personalized Medicine | Best Researcher Award

Cairo University | Egypt

Prof. Dr. Rabab Abdel Moneim is a distinguished authority in Clinical Oncology at the Kasr El Aini Faculty of Medicine, Cairo University, Cairo, Egypt. With an extensive career dedicated to cancer research, radiotherapy, and clinical practice, she has made a profound impact on oncology education, treatment innovation, and patient care across the Middle East. Her academic foundation was established at the renowned Kasr El Aini Faculty of Medicine, where she completed her M.B.B.Ch. degree with honors, followed by a master’s degree in Medical Oncology and Radiotherapy, earning the highest distinction across all Cairo universities. She later attained her Doctorate in Oncology, cementing her status as a leading scholar and clinician in the field.Prof. Abdel Moneim has accumulated rich professional experience through her long-standing affiliation with the Kasr El Aini Faculty of Medicine, where she has served in multiple academic and clinical capacities, advancing from house officer and resident to assistant lecturer, assistant professor, and eventually full professor. Her clinical expertise is reflected in her consultancy roles at the New Kasr El-Eini Teaching Hospital and the IMC Hospital Radiotherapy Center. Her early professional journey includes collaboration with Prof. Dr. Hamdy Abd El Azim at the Cairo Cure Center, a partnership that shaped her clinical vision and deepened her specialization in oncology and radiotherapy.Her professional experience extends beyond Egypt, having served as a consultant at King Fahd Hospital in Madina, Saudi Arabia, and maintaining an active registration with the Saudi Commission for Health Specialties in Oncology Medicine. Prof. Abdel Moneim’s commitment to global oncology advancement is further demonstrated through her participation in numerous international conferences and workshops, including ESMO, ESTRO, ASCO, and other major oncology congresses. Her contributions to evidence-based cancer therapy, radiotherapy techniques, and the facilitation of clinical trials across the MENA region have significantly influenced modern oncology practices.An active member of multiple professional societies such as ESTRO, ESMO, the Sarcoma Group, and the Neuro-Oncology Group at Cairo University, Prof. Abdel Moneim continues to contribute to academic excellence and clinical innovation. Her expertise in 3D conformal radiation therapy, stereotactic techniques, IMRT, and RapidArc has set a high standard in radiotherapy advancements. As a dedicated educator, she remains involved in postgraduate teaching and training programs, nurturing the next generation of oncologists.

Profile: Google Scholar

Featured Publications

Abdel Moneim, A. A. R., & El Deeb, M. (2017). Gingival pigmentation: Cause, treatment, and histological preview. Future Dental Journal.

Rady, D., Mubarak, R., & Abdel Moneim, R. A. (2018). Healing capacity of bone marrow mesenchymal stem cells versus platelet-rich fibrin in tibial bone defects of albino rats: An in vivo study. F1000Research.

Abdel Moneim, R. A., El Deeb, M., & Adel, F. (2018). Evaluation of the therapeutic potential of Tamarind seeds (aqueous extract) versus antidiabetic drugs on the histological structure of lingual papillae in diabetic rats. Egyptian Dental Journal, 64(3), Oral Medicine, X-Ray, Oral Biology Section.

Hakam, H. M., Abdel Moneim, R. A., & El Deeb, M. F. (2020). Osteoinductive potential and bone healing capacity of nanocrystalline hydroxyapatite (nHA) versus Biodentine of surgically created defects in rabbits’ alveolar process (an experimental study). Egyptian Journal of Histology.

Abdel Moneim, R. A., Mostafa, A., & Abbass, M. M. S. (2020). In treating glucocorticoid-induced osteoporosis in temporomandibular joint of albino rats; which are more effective: Microvesicles or mesenchymal stem cells? Egyptian Journal of Histology.

El Deeb, M., & Abdel Moneim, R. A. (2018). Remineralization potential of lactose-free and plant-based milk on enamel surface of human teeth subjected to energy drinks. Egyptian Dental Journal, 64(4), Oral Medicine, X-Ray, Oral Biology Section.

Ragaei, A., & Abdel Moneim, R. A. A. (2017). Gingival overgrowth: Drug-induced versus hereditary and idiopathic. Cosmetology & Oro Facial Surgery.

Biaoru Li | Personalized Medicine | Oncolog Oncopharm Research Achievement

Published on by Top Pharmaceutical

Dr. Biaoru Li | Personalized Medicine | Oncolog Oncopharm Research Achievement

Medical College of GA | United States

Dr. Biaoru Li is an accomplished leader in the fields of precision medicine, genomics, and personalized immunotherapy, with extensive experience spanning clinical hematology, oncology, and advanced molecular research. His expertise bridges the continuum from bio-specimen preparation to clinical application, integrating cutting-edge biobanking, primary cell sorting, single-cell identification, and functional genomics. Dr. Li’s research delves deeply into the cellular and molecular mechanisms that drive disease, with a particular focus on CD34 cells, erythroid cells, T-cells, and primary tumor cells. His work emphasizes the transformation of primary bio-specimens into powerful genomic insights through advanced technologies such as next-generation sequencing (NGS) and microarray analysis.A pioneer in precision medicine, Dr. Li has made substantial contributions to the development of personalized immunotherapy strategies and the integration of artificial intelligence into biomedical research. His ongoing projects include the design of AI-driven models that enhance diagnostic accuracy and therapeutic prediction for cancer and immune-related disorders. Dr. Li’s innovative research on single-cell RNA sequencing has opened new pathways for individualized treatment, offering a molecular-level understanding of disease heterogeneity.As an academic and clinical researcher, Dr. Li has established collaborations with hospitals and research institutions across the United States and Asia, promoting global scientific exchange and clinical translation. His scholarly impact is reflected in his numerous publications indexed in prestigious scientific databases such as SCI and Scopus, as well as his extensive citation record on Google Scholar and ORCID. Dr. Li’s editorial influence extends across 17 international editorial boards, where he contributes to advancing scientific standards in molecular medicine and clinical genomics.In addition to his academic achievements, Dr. Li has authored influential books, including Personalized Immunotherapy for Tumor Disease and Beyond and Personalized Therapy for PAH and Beyond, both of which underscore his leadership in developing targeted therapeutic frameworks. His membership in renowned professional societies, including the American Society of Hematology and the Royal Society of Medicine, underscores his commitment to advancing medical science and mentoring future researchers.

Profile: Orcid

Featured Publications

Li, S., & Li, B. (2025). Precision medicine related to landscape and architecture of tumor specimen. Japan Journal of Research.

Song, P., & Li, B. (2025). New generation of clinical epigenetics analysis and diagnosis for precision medicine. Diagnostics.

Palani, C. D., Smith, A., Cao, X., Li, B., Pace, B. S., & Starlard‐Davenport, A. (2025). Cholesterol‐conjugated miR‐29b induces fetal haemoglobin expression via γ‐globin promoter demethylation in the Townes mouse model for sickle cell anaemia. British Journal of Haematology.

Yang, Y., Chen, S., Li, W., Duan, J. C., Yuan, Y., Xie, V. S., & Li, B. (2024). STAT3 down-regulation for IL-2 inducing TIL-A clinical clue for spatial quantitative pathway analysis. AIMS Allergy and Immunology.

Li, B. (2024). Surgery and specimen biobanks—Tumor tissues and precision medicine. Journal of Surgery.

Li, B. (2024). Prediction, prevention, prognostic and personalized therapy of ovarian cancer—Biomarkers and precision medicine. Biomedical Journal of Scientific and Technical Research.

Yang, Y., Li, W., Chen, S., Yuan, Y., & Li, B. (2023). Spatial-timely quantitative network analysis for TGF-β pathway of tumor infiltrating lymphocytes. Journal of Cancer Science and Clinical Therapeutics.

Zhu, X., & Li, B. (Eds.). (2023). Epigenetics in cancer: Mechanisms and drug development – Volume II. Frontiers Research Topics.

Li, B. (2023). Personalized immunotherapy of patients: Defining by single-cell RNA-seq with artificial intelligence. Medical Research Archives.

Giorgio Gargari | Personalized Medicine | Best Paper Award

Published on by Top Pharmaceutical

Assist. Prof. Dr. Giorgio Gargari | Personalized Medicine | Best Paper Award

University of Milan | Italy

Assist. Prof. Dr. Giorgio Gargari is an accomplished researcher and academic in the Department of Food, Environmental and Nutritional Sciences at the University of Milan. His academic and research journey reflects a deep commitment to advancing the understanding of the intricate relationships between diet, the gut microbiome, and host physiology. With a strong foundation in biological sciences and food sciences, Dr. Gargari has developed expertise that bridges molecular biology, bioinformatics, and nutritional science, focusing on how dietary interventions influence microbiome composition and functionality. He is a highly skilled bioinformatician and biostatistician, proficient in computational biology, data analysis, and multi-omics integration. His work explores the triangular interaction between diet, microbiome, and host systems, aiming to elucidate how microbial ecosystems mediate the effects of food on health. His scientific approach integrates both experimental and computational methods to identify microbial pathways that contribute to human health and disease prevention. Dr. Gargari’s research has provided valuable insights into gut microbiome modulation through probiotics, polyphenol-rich diets, and microbial metabolites such as short-chain fatty acids. His publications demonstrate his capacity to translate complex biological data into clinically meaningful applications, particularly in the context of inflammatory regulation, gastrointestinal health, and precision nutrition.Dr. Gargari has published extensively in high-impact, peer-reviewed journals, contributing to a body of literature that continues to shape modern nutritional and microbiome research. His work has gained recognition in international conferences and scientific meetings, where he has been an invited speaker on topics such as microbial ecology in winemaking, gut microbiota modulation, and the metabolic effects of dietary components. He has also contributed to projects funded by major research institutions, coordinating studies on the transformation of agro-food waste into valuable biostimulants and microbial ecosystems for sustainable production.As an educator and academic leader, Dr. Gargari plays an active role in multiple degree programs, including Human Nutrition and Dietetics, Food Technology, and Bioinformatics for Comparative Genomics. He has supervised and mentored numerous students and has served on several thesis committees. His contributions to the scientific community have been recognized through various awards and international honors, reflecting his excellence in research, teaching, and innovation.

Profile: Orcid

Featured Publications

Gargari, G., Meroño, T., Peron, G., Del Bo’, C., Marino, M., Cherubini, A., Andres-Lacueva, C., Kroon, P. A., Riso, P., & Guglielmetti, S. (n.d.). Effect of a polyphenol-rich dietary pattern on subjects aged ≥ 60 years with higher levels of inflammatory markers: Insights into microbiome and metabolome. Microbiome Research Reports.

Marzano, M., Thakur, R. S., Bicciato, S., Raneri, M., Guglielmetti, S., Grassi, F., Mangani, D., De Ponte Conti, B., Pesole, G., Gargari, G., et al. (n.d.). Secretory IgA amplification during immune checkpoint blockade enhances the control of tumor growth by enterotropic T cells. Science Advances.

Laterza, L., Cremon, C., Coppola, G., Settanni, C. R., Maresca, R., Strazzeri, M., Durini, E., Petito, V., Scaldaferri, F., Gargari, G., et al. (n.d.). Multistrain probiotics plus vitamin D improve gut barrier function and gut microbiota composition in irritable bowel syndrome without constipation: Results from a double-blind, randomized, placebo-controlled trial. Nutrients.

Duncan, R., Mantegazza, G., Gargari, G., Pierallini, E., Russo, R., & Guglielmetti, S. (n.d.). Heyndrickxia coagulans LMG S-24828 is a safe probiotic strain capable of germinating in the human gut. Probiotics and Antimicrobial Proteins.

Gargari, G., Mantegazza, G., Taverniti, V., Gardana, C., Valenza, A., Rossignoli, F., Barbaro, M. R., Marasco, G., Cremon, C., Barbara, G., et al. (n.d.). Fecal short-chain fatty acids in non-constipated irritable bowel syndrome: A potential clinically relevant stratification factor based on catabotyping analysis. Gut Microbes.

Speciani, M. C., Gargari, G., Penagini, R., Mutignani, M., Ferraroni, M., Natale, A., Katsoulis, M., Cintolo, M., Leone, P., Airoldi, A., et al. (n.d.). Garlic consumption in relation to colorectal cancer risk and to alterations of blood bacterial DNA. European Journal of Nutrition.

Mutignani, M., Penagini, R., Gargari, G., Guglielmetti, S., Cintolo, M., Airoldi, A., Leone, P., Carnevali, P., Ciafardini, C., Petrocelli, G., et al. (n.d.). Blood bacterial DNA load and profiling differ in colorectal cancer patients compared to tumor-free controls. Cancers.

Pedro Moltó-Balado | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Pedro Moltó-Balado | Personalized Medicine | Best Researcher Award

Doctor at Ministry of Health | Spain

Dr. Pedro Moltó-Balado is a dedicated medical professional currently associated with the Ministry of Health, Spain. With a background in family and community medicine, he has combined clinical expertise with research innovation to advance patient care processes and public health initiatives. He has pursued advanced studies in biomedicine, patient care management, and headache specialization while contributing extensively to scientific publications across medical disciplines. His work encompasses cardiovascular health, mental health, primary care innovations, and clinical risk assessment, with a strong commitment to integrating machine learning and advanced diagnostic strategies in healthcare to enhance patient outcomes and medical decision-making.

Publication Profile 

Orcid

Education 

Dr. Pedro Moltó-Balado holds a Graduate in Medicine from Terres de l’Ebre Teaching Unit, Catalonia, Spain. He specialized in Family and Community Medicine through Francisco de Vitoria University and pursued a Ph.D. in Biomedicine from Rovira i Virgili University. Additionally, he completed postgraduate certifications as a University Expert in Headaches and in the Management of Patient Care Processes from Jaime I University and the University of Valencia, respectively. He has undergone specialized health training and participated in continuous academic development across medical law, healthcare management, and clinical research, strengthening his expertise in multidisciplinary healthcare and evidence-based medical practices.

Experience 

Dr. Pedro Moltó-Balado has been actively involved in healthcare practice and academic research through the Ministry of Health and academic institutions in Spain. He has contributed as a corresponding author and researcher in multiple peer-reviewed scientific journals, focusing on primary care innovations, cardiometabolic diseases, and neurological conditions. His professional engagements include clinical research in atrial fibrillation, stroke prevention, metabolic disorders, and rare medical conditions, along with implementing patient-centered healthcare strategies. He has also participated in academic teaching, supervising research projects, and contributing to medical education programs while collaborating with healthcare organizations to translate clinical research into practical healthcare solutions.

Awards and Honors 

Dr. Pedro Moltó-Balado has been recognized for his research contributions and academic excellence in family and community medicine, cardiometabolic health, and primary care innovation. His work on early diagnosis in cardiovascular medicine, clinical risk prevention, and rare disease case studies has been acknowledged through conference presentations, academic collaborations, and peer-reviewed scientific publications. He has contributed to international research forums and interdisciplinary projects that integrate clinical practice with technological innovation, including machine learning applications in healthcare. His commitment to advancing evidence-based medical practices has earned him recognition in medical research communities focused on improving public health outcomes.

Research Focus 

Dr. Pedro Moltó-Balado’s research focuses on cardiovascular risk prediction, primary care optimization, and integrating technology into clinical diagnostics. His studies explore early detection of atrial fibrillation, stroke prevention strategies, metabolic disorders, and neurological complications in primary healthcare settings. He has worked on machine learning models for predicting major adverse cardiovascular events, case studies on rare conditions such as pheochromocytoma and rhinocerebral mucormycosis, and management approaches for psychiatric medication complications. His multidisciplinary approach bridges clinical medicine, data analytics, and patient care strategies, aiming to develop innovative diagnostic tools and risk assessment methods that improve healthcare decision-making and patient safety outcomes.

Publication Top Notes

Estado de malnutrición como factor pronóstico de eventos cardiovasculares adversos mayores (MACE) en los pacientes con fibrilación auricular

Prediction of Major Adverse Cardiovascular Events in Atrial Fibrillation: A Comparison Between Machine Learning Techniques and CHA2DS2-VASc Score

Stroke Risk Stratification in Incident Atrial Fibrillation: A Sex-Specific Evaluation of CHA2DS2-VA and CHA2DS2-VASc

Stroke Risk Stratification in Incident Atrial Fibrillation: A Sex-Specific Evaluation of CHA2DS2-VA and CHA2DS2-VASc

Algo más que una coxalgia: necrosis avascular de cabeza femoral

Aripiprazole: Beware of pathological gambling addiction,Aripiprazol: cuidado con la adicción patológica al juego

Mucormicosis tras una picadura de araña

The Future of Healthcare: Biomedical Technology and Integrated Artificial Intelligence

Oleoma glúteo: consecuencias del tratamiento intramuscular

Machine Learning Approaches to Predict Major Adverse Cardiovascular Events in Atrial Fibrillation

Conclusion

Dr. Pedro Moltó-Balado’s academic achievements, innovative research in cardiometabolic and primary care medicine, and integration of technology into clinical diagnostics make him a highly suitable candidate for the Best Researcher Award. His dedication to improving patient outcomes through evidence-based research and his contributions to medical literature align well with the award’s objectives. With continued emphasis on global collaborations and translational research, his work has the potential to make significant advancements in public health and medical science.

Maria Garrido | Personalized Medicine | Women Researcher Award

Published on by Top Pharmaceutical

Dr. Maria Garrido | Personalized Medicine | Women Researcher Award

Doctor at Hospital Universidtario 12 de octubre-Universidad Complutense de Madrid | Spain

Dr. Maria Garrido is a physician-scientist specializing in pathology and translational oncology with a focus on melanoma and cutaneous lymphomas. She earned her medical degree from the University of Granada and her PhD in Health Sciences and Biomedicine from Universidad Complutense de Madrid. With extensive international experience at the University of California San Francisco and Memorial Sloan Kettering, her research has contributed to landmark discoveries in oncogenes, fusion kinases, and tumor biomarkers. She currently works in dermatopathology and oncology research, collaborating with leading groups in Europe and internationally to advance personalized cancer diagnostics and therapeutic strategies.

Publication Profile 

Orcid

Education 

Dr. Maria Garrido obtained her medical degree in Medicine and Surgery from the University of Granada. She pursued her residency in Anatomical Pathology at Hospital Universitario 12 de Octubre, Madrid, and later completed a PhD in Health Sciences and Biomedicine at Universidad Complutense de Madrid. Complementing her medical and scientific training, she earned a Master’s in Clinical Management, Medical, and Healthcare Leadership from Universidad Tecnológica. Her academic formation integrates rigorous clinical foundations with molecular oncology research, allowing her to bridge patient care and translational science. She has continued to enhance her expertise through national and international academic fellowships.

Experience 

Dr. Maria Garrido has served as a resident and clinical specialist in pathology at major Spanish hospitals, including Hospital 12 de Octubre, Hospital General de Móstoles, and Clinic Hospital of Barcelona. Internationally, she was a fellowship researcher at UCSF and Memorial Sloan Kettering, contributing to melanoma genetics and translational oncology. She has collaborated on groundbreaking discoveries, including oncogenes in uveal melanoma and fusion kinases in Spitz tumors. Currently, she is part of the dermatopathology and oncology research group at Hospital Universitario 12 de Octubre, Madrid, where she advances studies on melanoma, lymphomas, molecular biomarkers, and diagnostic innovations in cutaneous oncology.

Awards and Honors 

Dr. Maria Garrido has received notable recognition for her research contributions. She was awarded a mobility fellowship by the Spanish Ministry of Science and Innovation for professional development in computational pathology at Queen’s University, Belfast. Her discoveries, including the GNA11 oncogene and fusion kinases in melanocytic tumors, have been published in high-impact journals such as the New England Journal of Medicine, Nature Communications, and Nature Genetics. Her contributions to the field of melanoma genetics have been cited worldwide, shaping the understanding of tumor biology. She continues to be honored through invitations to collaborate on international research initiatives and networks.

Research Focus 

Dr. Maria Garrido research focuses on the molecular pathology of melanoma and cutaneous lymphomas. She has made significant contributions to identifying oncogenes such as GNA11 and GNAQ, which account for most uveal melanomas, and discovering kinase fusion proteins in Spitz tumors. Her work also includes genetic studies on desmoplastic melanoma highlighting NFKBIE mutations. More recently, she has contributed to refining the classification of cutaneous lymphomas and identifying new biomarkers to guide diagnosis, prognosis, and therapeutic response. Her approach integrates pathology, molecular biology, and translational medicine to improve personalized treatment strategies and enhance patient outcomes in oncology and dermatopathology.

Publication Top Notes

Advanced Periocular Basal Cell Carcinoma with Orbital Invasion: Update on Management and Treatment Advances

Acute sarcoidosis as a harbinger for pancreatic adenocarcinoma

TERT promoter mutation in sebaceous neoplasms

Orbital Solitary Fibrous Tumor: Four Case Reports—Clinical and Histopathological Features

Conjunctival Tarsal Actinic Keratosis Treated with Interferon Alfa-2b: A Rare Case Report and Literature Review

SARS‐CoV‐2 endothelial infection causes COVID‐19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases

Prognostic implications of markers of the metabolic phenotype in human cutaneous melanoma

Jonathan Ejie | Personalized Medicine | Best Research Article Award

Published on by Top Pharmaceutical

Jonathan Ejie | Personalized Medicine | Best Research Article Award

Mr. Jonathan Ejie, UCSF, United States

Mr. Jonathan Ejie is an aspiring physician-scientist currently pursuing his M.D. at UCSF 🩺 (Class of 2026), following a B.S. in Electrical Engineering & Computer Science from UC Berkeley 💻. His research spans oncology, radiology, and AI in healthcare, with published work in Cancers (2025) and upcoming studies in Nature Communications 📊. Jonathan integrates data science 🧠 with clinical insights, contributing to health equity, quality improvement, and surgical education. A mentor, tutor, and award-winning leader 🏅, he co-founded the UCSF Futbol Club and serves underserved communities through advocacy and outreach.

Publication Profile 

Orcid

Education

Mr. Jonathan Ejie is an exceptional scholar whose educational journey bridges medicine and technology. He is currently pursuing his Doctor of Medicine (M.D.) degree at the prestigious University of California, San Francisco (UCSF) 🏥, with an expected graduation in 2026. Prior to this, he earned a Bachelor of Science in Electrical Engineering and Computer Science (EECS) 💻 from the University of California, Berkeley, graduating in 2022. His strong foundation in both engineering and clinical science equips him with a unique interdisciplinary perspective 🤖🩺, positioning him at the forefront of innovation in digital health and precision medicine.

Experience

Mr. Jonathan Ejie brings a blend of academic support and compassionate service to his professional journey. As an MCAT Physics Tutor at UCSF (2023), he guided 15+ students through complex physics concepts 📘⚛️. Earlier, at Contra Costa College (2019–2021), he tutored mathematics from Algebra to Calculus ➕📐. His volunteer work includes providing first aid at athletic events 🏃‍♂️🩹, teaching surgical skills to high school students at UCSF 🧵🧑‍⚕️, and serving as a Health Advocate at West County Health Center 💬🩺, helping underserved patients access vital community resources. His dedication reflects a strong commitment to both education and public health.

Awards

Mr. Jonathan Ejie has been recognized for his academic excellence and impactful contributions to medicine and research. In 2024, he was honored with the prestigious Sinkler Miller Medical Association Scholarship 🎖️, sponsored by Gilead, celebrating his commitment to health equity and academic distinction. He also received the UCSF School of Medicine Summer Explore Fellowship Grant 🌟, supporting his innovative pursuits in medical research. In May 2023, Jonathan earned the Inquiry Conference Travel and Dissemination Award ✈️📊, which enabled him to share his scholarly findings on a larger stage. These accolades reflect his rising potential and leadership in healthcare.

Research Focus 

Mr. Jonathan Ejie’s research focus lies at the intersection of oncology, health disparities, and medical data science. His standout work on the “Ongoing Failure to Deliver Guideline-Concordant Care for Patients with Pancreatic Cancer” 📉🩺 highlights critical inequities in healthcare delivery across race, geography, and insurance status. Combining his background in medicine 🧑‍⚕️ and computer science 💻, Jonathan leverages data analysis and machine learning 🤖📊 to drive systemic improvements in cancer care. His work reflects a commitment to equity, evidence-based medicine, and the pursuit of personalized, accessible treatment strategies for vulnerable cancer populations.

Publication Top Notes

  • Ongoing Failure to Deliver Guideline-Concordant Care for Patients with Pancreatic Cancer

Mario Romeo | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Mario Romeo | Precision Medicine | Best Researcher Award

Dr. Mario Romeo, Dipartimento di Medicina di Precisione, Università degli Studi della Campania, LuigiVanvitelli, Italy

Dr. Mario Romeo is an accomplished medical doctor and researcher specializing in Digestive System Diseases. Graduating with top honors in Medicine and Surgery from the University of Campania “Luigi Vanvitelli” 🎓, he also earned a specialization in Gastroenterology and is pursuing a Ph.D. in Clinical and Experimental Medical Sciences. His research spans gut microbiota 🧫, liver disease 🏥, and metabolic dysfunction. A recipient of over 20 international awards 🏆, Dr. Romeo is widely recognized for his groundbreaking work in hepatology and gastroenterology. He actively contributes to scientific societies and fosters innovation in digestive health care.

Publication Profile 

Orcid

Education

Dr. Mario Romeo 🎓 began his academic journey with honors, earning his Diploma di Maturità Classica from Liceo Classico Gneo Nevio in June 2014 with a perfect score of 100/100 con lode 📜. He continued his excellence at the University of Campania “Luigi Vanvitelli,” completing his Laurea in Medicina e Chirurgia in July 2020 with 110/110 con lode 🩺, presenting a thesis on sarcopenia in compensated liver cirrhosis. He further specialized in Digestive System Diseases, earning his diploma in January 2025 with 50/50 con lode 🌟. His thesis explored RPR as a non-invasive tool in liver disease prediction.

Awards

Dr. Mario Romeo 🏅 has received numerous prestigious scholarships and awards in recognition of his excellence in hepatology and gastroenterology. Highlights include competitive fellowships like the AISF MasterClass 2022 🎓 and UEG Clinical Visiting Fellowship 2025 🌍. He has earned multiple travel grants ✈️ and best presentation prizes 🏆 at top events such as UEG Week, FISMAD, EASL, and ESCI for groundbreaking research on liver diseases, MAFLD, gut microbiota, and non-invasive biomarkers. His multidisciplinary “CoCoNut” protocol 🍏 also gained international acclaim. These accolades affirm his dynamic role in advancing liver research and patient care through innovation and collaboration.

Research Focus 

Dr. Mario Romeo’s research focus lies predominantly in Hepatology and Gastroenterology, with a strong emphasis on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), liver cirrhosis, and gut-liver axis dynamics 🧬🍽️. His work explores non-invasive biomarkers, body composition, oxidative stress, and gut microbiota 🧫, highlighting their roles in disease progression and clinical outcomes. He also investigates multidisciplinary management strategies combining nutritional, psychological, and pharmacological interventions 🥗🧠💊. Dr. Romeo contributes significantly to understanding liver-related complications like sarcopenia, dysgeusia, and hepatocellular carcinoma 🎯. His innovative, patient-centered research enhances predictive diagnostics and therapeutic approaches in chronic liver diseases.

Publication Top Notes

  • Spleen Area Affects the Performance of the Platelet Count–Based Non-invasive Tools in Predicting First Hepatic Decompensation in Metabolic Dysfunction–Associated Steatotic Liver Disease Cirrhosis
  • Nutritional and Psychological Support as a Multidisciplinary Coordinated Approach in the Management of Chronic Liver Disease: A Scoping Review
  • Letter: Different Risk of Acute Variceal Bleeding According to the Liver Disease Aetiology in Decompensated Cirrhosis Patients Receiving Carvedilol‐Based Primary Prophylaxis—May Insulin Resistance Unloose This Gordian Knot?
  • Exploring the Classic and Novel Pathogenetic Insights of Plastic Exposure in the Genesis and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  • The Role of the Gut–Biliary–Liver Axis in Primary Hepatobiliary Liver Cancers: From Molecular Insights to Clinical Applications
  • Primary biliary cholangitis, Celiac Disease, and MASLD: the triumvirate of steatosis. How should we manage this triple overlap?
  • Clinical Applications of Artificial Intelligence (AI) in Human Cancer: Is It Time to Update the Diagnostic and Predictive Models in Managing Hepatocellular Carcinoma (HCC)?
  • FLAME: Training and Validating a Newly Conceived Model Incorporating Alpha-Glutathione-S-Transferase Serum Levels for Predicting Advanced Hepatic Fibrosis and Acute Cardiovascular Events in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  • Dysgeusia in MASLD-related advanced chronic liver disease (ACLD): a silent driver towards the “Bermuda” triangle of malnutrition-sarcopenia-frailty severely affecting prognosis
  • Vanek’s Tumour as a Rare Cause of Dyspeptic Syndrome in a Patient with Primary Biliary Cholangitis: A Case Report
  • Systemic Oxidative Stress Correlates with Sarcopenia and Pruritus Severity in Primary Biliary Cholangitis (PBC): Two Independent Relationships Simultaneously Impacting the Quality of Life—Is the Low Absorption of Cholestasis-Promoted Vitamin D a Puzzle Piece?
  • Prediction of Clinical Trajectory in HCV-Related ACLD after SVR: Role of Liver Stiffness in a 5-Years Prospective Study

Salma Khan | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Salma Khan | Precision Medicine | Best Researcher Award

Assoc. Prof. Dr. Salma Khan, Loma Linda University, United States

Assoc. Prof. Dr. Salma Khan is a distinguished physician-scientist specializing in gynecologic oncology and thyroid cancer research. With a Ph.D. from Kumamoto University 🇯🇵 and faculty appointments at Loma Linda University 🏥, she excels in translational cancer biology. Her groundbreaking work on health disparities, molecular oncology, and thyroid cancer genomics has earned her multiple honors, including the 2024 AACR Women Cancer Research Award 🌟. She actively contributes to the American Thyroid Association, NIH peer review panels, and serves on several journal editorial boards 📚. Dr. Khan is also a dedicated mentor and advocate for diversity in science and medicine .

Publication Profile

Google Scholar

Education

Assoc. Prof. Dr. Salma Khan began her academic journey with a Higher Secondary Certificate from Govt. M.M. Ali College, Tangail, Bangladesh (1983–1985). 🎓 She earned her MBBS from Gandhi Medical College, Bhopal, India (1986–1991), followed by an internship at Hamidia Hospital (1991–1992). 🏥 Dr. Khan completed her residency in Obstetrics and Gynecology at IPGMR, Dhaka (1992–1994), and pursued a fellowship at Kumamoto University School of Medicine, Japan (1995–1996). 🌸 Her academic excellence culminated in a Ph.D. in Gynecologic Oncology from Kumamoto University (1996–2000), showcasing her dedication to advancing women’s health.

Awards

Assoc. Prof. Dr. Salma Khan has received numerous accolades throughout her distinguished career. She was honored with the Best Mentor Award by BMANA in 2025 (San Francisco), 2023 (Los Angeles), and 2020 (Dallas). 🌟 In 2024, she received the AACR Women Cancer Research Award and the Best Basic Science Research Award in California. 🎗️ A frequent recipient of Travel Awards from the American Thyroid Association (2016–2023), Dr. Khan also earned top honors at scientific meetings and was a keynote speaker in Japan and Korea (2015). 🌍 Her journey began with prestigious academic scholarships in Bangladesh, India, and Japan.

Research Focus

Assoc. Prof. Dr. Salma Khan focuses her research on cancer biology, with a specialized emphasis on exosomes, survivin biology, and biomarkers for early cancer detection, particularly in prostate and breast cancers. Her groundbreaking studies explore how tumor-derived exosomes contribute to cell signaling, apoptosis inhibition, and metastasis, highlighting survivin as a pivotal player and potential diagnostic marker. Dr. Khan’s work intersects molecular oncology and translational medicine, aiming to bridge lab findings with clinical applications. Her contributions are instrumental in advancing non-invasive diagnostic tools and improving cancer prognosis across diverse populations.

Publication Top Notes

Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer

Survivin is released from cancer cells via exosomes

Early diagnostic value of survivin and its alternative splice variants in breast cancer

Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential

PTEN promoter is methylated in a proportion of invasive breast cancers

Human villous macrophage-conditioned media enhance human trophoblast growth and differentiation in vitro

Differential MicroRNA‐Signatures in Thyroid Cancer SubtypesProteomic profiling of serum-derived exosomes from ethnically diverse prostate cancer patients

Exosomes secreted from human cancer cell lines contain inhibitors of apoptosis (IAP)

LATS1 phosphorylates forkhead L2 and regulates its transcriptional activity

The emerging role of exosomes in survivin secretion

Curcumin induces pancreatic adenocarcinoma cell death via reduction of the inhibitors of apoptosis

juan iovanna | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

juan iovanna | Personalized Medicine | Best Researcher Award

Prof. Dr. juan iovanna, INSERM, France

Prof. Dr. Juan Iovanna è un medico e ricercatore internazionale esperto in oncologia, specializzato nello studio del carcinoma pancreatico. Laureato e dottorato all’Università di Buenos Aires, lavora in Francia dal 1991 presso l’INSERM, dove ha raggiunto il grado di Direttore di Ricerca di Classe Eccezionale. Co-dirige il gruppo “Biologia del cancro pancreatico” al CRCM di Marsiglia e presiede il Programma G7 Cancer. Fondatore di tre start-up biotecnologiche, ha pubblicato 472 articoli con oltre 43.500 citazioni 📚. La sua missione è migliorare la prognosi del tumore pancreatico attraverso ricerca e innovazione terapeutica.

Publication Profile

orcid

Education

Prof. Dr. Juan Iovanna began his academic journey with a degree in Medicine from the University of Buenos Aires, Argentina, in 1982. Driven by a passion for biomedical research, he pursued a Ph.D. in Biomedical Sciences at the same university, which he completed in 1986. 🧬 His doctoral thesis, titled “Meccanismi di regolazione della sintesi proteica in modelli cellulari di stress,” focused on the mechanisms regulating protein synthesis in cellular stress models. 🧪 This foundational work laid the groundwork for his future contributions to medical science and molecular biology.

Experience

🔬 Prof. Dr. Juan Iovanna has built an illustrious career in cancer research. In 1991, he began as a researcher at INSERM in France and was promoted to Research Director in 1993 and again in 1998. 🚀 In 2011, he achieved the prestigious title of Directeur de Recherche de Classe Exceptionnelle (DRCE). From 2011 to 2023, he served as Vice-Director of the Marseille Cancer Research Center (CRCM) and led its Translational Medicine Department. 🧫 He also directed the “Pancreatic Cancer Biology” group from 1999 to 2023. Since 2024, he co-directs this group with Dr. Nelson Dusetti and serves as Emeritus Research Director.

Distinctions and Awards

Prof. Dr. Juan Iovanna has received numerous prestigious awards and honors throughout his career. In 2017, he was awarded the Jean Valade Prize by the Fondation de France for his outstanding contributions to biomedical research. 🌍 In 2018, he received the RAICES Award from Argentina’s Ministry of Science, Technology, and Innovation. 🇫🇷 In 2021, the French Senate honored him with a commemorative medal. In 2023, he was named Honorary Professor at the National University Arturo Jauretche (UNAJ), and in 2024, he was recognized as a Distinguished and Honorary Member of the University of Buenos Aires.

Research Focus

Prof. Dr. Juan Iovanna’s research is centered on precision oncology, with a primary focus on pancreatic ductal adenocarcinoma (PDAC). His work integrates transcriptomics, drug resistance mechanisms, redox metabolism, and multi-omics modeling to uncover novel therapeutic vulnerabilities and biomarkers. He contributes to the development of RNA signatures (like GemPred) to predict chemotherapy response, and investigates KRAS inhibition and therapy-induced senescence as pathways to reverse drug resistance. His translational studies aim to optimize personalized treatment strategies for pancreatic cancer patients, bridging molecular insights with clinical application.

Publication Top Notes

KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adenocarcinoma

The PancreasView gemcitabine transcriptomic signature predicts response to gemcitabine in patients with resected pancreatic ductal adenocarcinoma

Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic cancer

Reply to the Letter to the Editor regarding ‘Chi-squared and P-values vs. machine learning feature selection by Y. Takefuji’

Reply to the Letter to the Editor ‘AI-assisted personalized adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma’ by Y. Shimazu

Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial
Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity
Limitation and challenges in using pancreatic cancer‐derived organoids as a preclinical tool

Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction